GSK’s Emma Walmsley to step down as chief executive after eight years | GSK

Britain’s second largest drug producer GSK announced that Emma Walmsley, chief manager eight years later, left a surprise.

Walmsley, which has been running FTSE 100 since 2017, will resign from the board of directors at the end of this year and will remain at work until the end of September 30, 2026.

Luke Miels, the head of trade in the company since 2017, will replace it and start on January 1st.

GSK shares increased by more than 3% on Monday morning and became the best amplifier in the FTSE 100 index.

Dame Walmsley, who managed the drug producer’s consumer’s health business before the best work, has supervised significant changes, including the largest institutional restructuring of 2022, 2022’s brands such as Sensodyne, Panadol and Advil.

GSK’s new drug pipeline remained behind the competitors, but when he took over from Sir Andrew Witty, he weakened to focus on “real winners ve and sharpen focus on special drugs and vaccines.

Walmsley said: “2026 is a very important year for GSK to define its path for the next decade and I believe the right moment for the new leadership.

“As CEO, you hope to leave your favorite company stronger than you find and prepare for uninterrupted successor.

Miels was boiled from the United Kingdom rival Astrazeneca, and Walmsley was launched as a potential successor when an activist investor Elliott Management, who criticized the low performance of the years and demanded changes in the summit in 2021, was intensively pressure from Elliott Management.

However, Walmsley successfully defended Elliott’s pressure, and a few months later, the company recovered the transfer proposals for the consumer health branch and from Dove Maker Unilever, the last valuable GSK.

Walmsley, one of Britain’s most well -known business women, joined the Prime Minister Business Council in mid -2013 under the direction of Rishi altar and recently joined Donald Trump’s state feast at Windsor Castle during his visit to England.

Walmsley, as a result of lower bonuses in 2023 in 2023, £ 12.7 million pounds, last year with a package of 10.6 million pounds is one of the highest paid chief managers. The fixed wage changed by 1.6 million pounds.

While Miels will receive a salary of £ 1.38 million, performance-related bonuses are set on the same salary floors-up to 300% of the 150% annual bonus and salary. In addition, eight times the salary for the 2027 grant rises for a long -term stock bonuses of 7.25 times salary.

The separation of Walmsley will leave the FTSE 100 with only seven women with chief administrators: Milena Mondini de Focatiis Admiral, Amanda Blanc in Aviva, Allison Kirkby in CT, Stella David in Entin, Liv Garfield in Severn Trent, Louise Beardmore in United Utilities and Margherita della Valle in Vodafone.

GSK President Sir Jonathan Symonds thanked Walmsley for his extraordinary leadership in presenting a strategic transformation of the GSK, including Haleon’s Dememerger, and that the business was “a brilliant and ambitious future”.

Hargreaves Lansdown Derren Nathan said: “There is an exciting pipeline for the next time, and this year GSK alone on its way for five major regulatory approval.

Despite Walmsley’s agreement, the share price performance was lifeless, Nathan and the company’s growth rates were stuck in the single -digit area, he said.

Shore Capital Analyst Sean Conroy said Miels was a good positioning to lead GSK for the rest of the decade because he tried to fulfill the ambition of £ 40 billion Plus 2031 ”.

GSK, headquartered in London, employs more than 65,000 people worldwide. It is one of the largest companies listed on the London Stock Exchange with a market value of £ 60 billion.

Walmsley’s separation comes in a difficult time in the pharmaceutical industry because Trump threatens to apply new tariffs to branded drugs this week.

Drug producers are also locked with the British government on the pricing of new drugs, and other companies – with the US MSD and Eli Lilly – paused or engraved significant investments in the UK.

GSK emphasized its loyalty to the UK, while two weeks ago, the United States announced the new investment in production and research. On Monday, Astra said it was preparing to directly list their shares directly on the New York Stock Exchange, but will be listed in London.